Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 9/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25156379 | 0.85 | AKT1 (0.51) | PDE2AAKT1HDAC1PPARGPPARA | |
| SCHEMBL22686802 | 0.80 | AKT1 (0.41) | PDE2AAKT1P2RY14RORCHDAC3 | |
| SCHEMBL19282949 | 0.80 | PDE2A (0.51) | PDE2AHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18551335 | 0.80 | MIF (0.46) | PDE2AAKT1RORC | |
| SCHEMBL12196127 | 0.79 | DRD2 (0.53) | PDE2AAKT1HDAC3HDAC1HDAC2 | |
| SCHEMBL2588632 | 0.79 | NPC1 (0.47) | PDE2AAKT1RORC | |
| SCHEMBL5640967 | 0.79 | AKT1 (0.43) | PDE2AAKT1RORCOPRM1 | |
| SCHEMBL23778486 | 0.79 | AKT1 (0.45) | PDE2AAKT1 | |
| SCHEMBL14236180 | 0.79 | AKT1 (0.43) | PDE2AAKT1RORC | |
| SCHEMBL4087871 | 0.79 | AKT1 (0.43) | PDE2AAKT1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247336-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247336-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | PDE2A 962/4885AKT1 2274/4885P2RY14 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.